Repeated Herbal Acupoint Sticking Relieved the Recurrence of Allergic Asthma by Regulating the Th1/Th2 Cell Balance in the Peripheral Blood
Repeated Herbal Acupoint Sticking Relieved the Recurrence of Allergic Asthma by Regulating the Th1/Th2 Cell Balance in the Peripheral Blood
复制标题
反复中药穴位贴敷通过调节外周血Th1/Th2细胞平衡缓解过敏性哮喘复发
DOI：
10.1155/2020/1879640
复制
发表时间：
2020-05-18
影响因子：
--
通讯作者：
Cao, Meng
中科院分区：
文献类型：
--
作者：
Zhao, Shu-Mei;Wang, He-Sheng;Cao, Meng
过敏性哮喘是一种外周血Th 1/Th 2细胞失衡的炎症性疾病。中药反复穴位贴敷（RHAS）在中国已经使用了数百年，以缓解过敏性哮喘的复发，直到今天仍然在实践。因此，我们在本研究中探讨了对过敏性哮喘复发的影响和潜在的免疫调节机制。在这里，我们招募了50名过敏性哮喘参与者，其中38人完成了治疗和随访（过敏性哮喘组）。此外，还招募了13名健康参与者（对照组）。采用哮喘控制试验（ACT）和哮喘复发次数评价治疗对缓解过敏性哮喘复发的作用。采用流式细胞仪检测外周血Th 1、Th 2细胞水平。ELISA法检测血清IgE、IFN-γ、IL-4水平。(1)过敏性哮喘组末次治疗结束时、治疗18周、治疗30周时与首次治疗前相比，哮喘复发例数减少，ACT评分增加（P < 0.05）。试验18周和30周时，过敏性哮喘组复发例数少于去年同期，ACT评分高于去年同期（P < 0.05）。末次治疗结束时，过敏性哮喘组与首次治疗前比较，Th 1细胞百分率无明显变化，Th 2细胞百分率下降，Th 1/Th 2细胞比值升高（P < 0.05）。过敏性哮喘组IgE、IL-4的释放减少（P < 0.05），IFN-γ的释放无明显变化。(2)与对照组比较，过敏性哮喘组血清IgE、IL-4水平及Th 2细胞百分比升高，Th 1/Th 2细胞比值降低（P < 0.05）。首次治疗前Th 1细胞和IFN-γ无显著性差异。(3)与对照组比较，过敏性哮喘组IgE水平和Th 2细胞百分比均升高（P < 0.01）。末次治疗结束时，Th 1细胞、Th 1/Th 2细胞比值、血清IFN-γ和IL-4水平均无显著性差异。提示RHAS可降低Th 2细胞数量，提高Th 1/Th 2细胞比值，从而减轻过敏性哮喘患者的炎症反应。
Allergic asthma is an inflammatory disease involving the Th1/Th2 cell imbalance in the peripheral blood. Repeated herbal acupoint sticking (RHAS) has been used for hundreds of years in China to relieve the recurrence of allergic asthma, and it is still practiced today. Thus, we explored the effect on allergic asthma relapse and the underlying immunoregulatory mechanism in this study. Here, we enrolled 50 allergic asthma participants, and 38 of them completed the treatment and follow-up (the allergic asthma group). In addition, 13 healthy participants (the control group) were enrolled. The recurrence number of allergic asthma participants and asthma control test (ACT) were used to evaluate the effect of treatment on relieving allergic asthma recurrence. Flow cytometry was performed to analyze the levels of Th1 and Th2 cells in the peripheral blood. The serum levels of IgE, IFN-γ, and IL-4 were detected by ELISA. (1) In the allergic asthma group, compared to before the first treatment, the recurrence number of allergic asthma participants decreased and the ACT score increased at end of the last treatment, 18 and 30 weeks of the trial (P < 0.05). At 18 and 30 weeks of the trial, the recurrence number of allergic asthma participants was less and the ACT score was higher than the ones from the same period last year in the allergic asthma group (P < 0.05). Compared to before the first treatment, the percentage of Th1 cell did not change significantly, the percentage of Th2 cell decreased, and the Th1/Th2 cell ratio increased in the allergic asthma group by the end of the last treatment (P < 0.05). Meanwhile, the release of IgE and IL-4 reduced (P < 0.05), and the release of IFN-γ did not significantly change in the allergic asthma group. (2) Compared with the control group, the serum levels of IgE and IL-4 and the percentage of Th2 cell were higher, and the Th1/Th2 cell ratio was lower in the allergic asthma group (P < 0.05). There was no significant difference between Th1 cell and IFN-γ before the first treatment. (3) Compared with the control group, the IgE levels and the percentage of Th2 cell were higher in the allergic asthma group (P < 0.01). Simultaneously, there was no significant difference between Th1 cell, the Th1/Th2 cell ratio, and the serum levels of IFN-γ and IL-4 by the end of the last treatment. The data suggested that RHAS reduced the amount of Th2 cell and elevated the Th1/Th2 cell ratio, thereby alleviating the inflammatory responses in the allergic asthma participants.